Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 24, 2015 Research ... of the "Global Array Instruments Market 2015-2019" ... global array instruments market to grow at a ... The global array instruments market can be ... and others including tissue microarrays and cell microarrays. ...
(Date:6/30/2015)... 2015  Inari Medical, Inc. announced today that it ... financing. The financing was led by members of the ... US Venture Partners.  The round also included participation by ... very pleased to complete this financing with the support ... , who joined in February 2015 as President and ...
(Date:6/30/2015)... ALISO VIEJO, Calif. , June 30, 2015 ... from the PRISM II study showing that treatment ... statistically significant reduction in symptoms of pseudobulbar affect ... or stroke. PBA is a distressing condition characterized ... crying resulting from certain neurologic diseases or brain ...
Breaking Medicine Technology:Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:6/30/2015)... , ... June 30, 2015 , ... ... customers. As a subcontractor, ESSC ranked as one of their top 20 installing ... the last quarter of 2014. Providers are based on timeliness, service, installation, paperwork ...
(Date:6/30/2015)... ... , ... Ticket Down is a reliable source for cheap tickets for Journey at the ... band has been packing venues for years and they are one of the most beloved ... in their career. While Journey is known for their all-around great sound, fans of ...
(Date:6/30/2015)... ... June 30, 2015 , ... The board certified otolaryngologists ... design’ website to inform potential sinus surgery patients about ear, nose, and throat ... information about a wide variety of ENT issues including hearing loss, ear infections, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier this month Wound ... Medicine Course. Clinicians from WCA partnering hospitals across the country, met in Anaheim, ... care and hyperbaric medicine education and training is something that is never complete. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... YouTube video, “Fireside Convalescent Care Center.” The video informs community members of Fireside’s ... continually seeing the need for those seeking care to be well informed and ...
Breaking Medicine News(10 mins):Health News:Electronic Security Specialists (E.S.S.C. Inc) Awarded Top Service Provider Award By Monitronics 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2
... breast cancer patient has to pay thousands of dollars as ... case against the doctor//. Doctor Robert Newton is the family ... case for negligent treatment as they feel that the doctor ... case against Dr. Newton for a compensation of $2million for ...
... seen when Pharma major Wockhardt limited (Thiruvananthapuram) in association with ... vaccine//, marketed the latest vaccine for Hepatitis A. ,Hepatitis ... to be taken to curb the spread of the disease. ... period of almost a month and spreads to humans through ...
... arguments can delay wound healing according to a new study ... New Scientist//. ,.,Researchers at Ohio State University College of ... about half hour daily can have delayed wound healing at ... also cause reduced body immunity. ,42 married couples whose ...
... stabilize the rates of HIV by the year 2020 has ... HIV infected individuals on a monthly basis//. It has also ... below 0.3 percent by 2010. The current projected population of ... recent government decision, poor HIV carriers living in communities are ...
... Her-2/neu positive was helped by her Wangaratta community to ... costs her more than $70,000.// The fund was raised ... could help her to buy Herceptin drug for one ... to chemotherapy and anti-estrogen therapy such as tamoxifen and ...
... novel finding that love and addiction may go hand ... physiological effects manifested as a result of dopamine release// ... than a simulation of the effects observed following drug ... and drug abuse leaves the user with an insatiable ...
Cached Medicine News:Health News:‘Marriage Squabbles’ bad for both Emotional and Physical Wound 2Health News:Love And Drug Addiction Share The Same Chemistry 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: